Literature DB >> 25016792

[One year outcomes of pars plana vitrectomy in proliferative diabetic retinopathy].

Masaki Tadera, Hajime Kawamura, Masato Fujikawa, Masashi Kakinoki, Tomoko Sawada, Yoshitsugu Saishin, Masahito Ohji.   

Abstract

PURPOSE: To evaluate the 1-year results of pars plana vitrectomy for proliferative diabetic retinopathy. PATIENTS AND METHODS: Two hundred thirty six patients with proliferative diabetic retinopathy received primary vitreous surgery at Shiga University of Medical Science Hospital and had at least 1 year follow-up period. The indications for pars plana vitrectomy included vitreous hemorrhage in 140 eyes, extramacular tractional retinal detachment in 60 eyes, macular tractional retinal detachment in 24 eyes and combined tractional retinal detachment in 12 eyes. The visual acuity and changes in visual acuity at 1-year postoperatively were evaluated. Preoperative bevacizumab injection and postoperative visual outcomes were compared between patients treated with 20 gauge (20 G) surgery and with micro incision vitrectomy surgery (MIVS).
RESULTS: The visual acuity improved by 3 lines or more in 166 eyes (70%) and remained unchanged in 56 eyes (24%); it decreased by 3 lines or more in 14 eyes (6%). Tractional retinal detachment in MIVS received more bevacizumab injections. MIVS systems achieved better visual results in the combined tractional retinal detachment group than 20 G system.
CONCLUSION: Successful visual improvement at 1-year postoperatively was observed in eyes with proliferative diabetic retinopathy after pars plana vitrectomy. Results of this study may suggest the superior performance of MIVS for pars plana vitrectomy in proliferative diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25016792

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  1 in total

1.  Factors correlated with visual outcomes at two and four years after vitreous surgery for proliferative diabetic retinopathy.

Authors:  Katsuhiro Nishi; Koichi Nishitsuka; Teiko Yamamoto; Hidetoshi Yamashita
Journal:  PLoS One       Date:  2021-01-14       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.